Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | GLS | O94925 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084749 | 1.00 | MEN1 (0.38) | MEN1ALDH1A1MAPTKMT2AGPR119 | |
| SCHEMBL2084747 | 1.00 | MEN1 (0.38) | MEN1ALDH1A1MAPTKMT2AGPR119 | |
| SCHEMBL1498900 | 0.86 | MEN1 (0.41) | MEN1ALDH1A1MAPTKMT2AGPR119 | |
| SCHEMBL1498897 | 0.86 | MEN1 (0.41) | MEN1ALDH1A1MAPTKMT2AGPR119 | |
| SCHEMBL1498898 | 0.86 | MEN1 (0.41) | MEN1ALDH1A1MAPTKMT2AGPR119 | |
| SCHEMBL1498807 | 0.80 | GPR119 (0.44) | MEN1ALDH1A1MAPTKMT2AGPR119 | |
| SCHEMBL2085183 | 0.80 | GPR119 (0.44) | MEN1ALDH1A1MAPTKMT2AGPR119 | |
| SCHEMBL2087770 | 0.80 | GPR119 (0.44) | MEN1ALDH1A1MAPTKMT2AGPR119 | |
| SCHEMBL2087767 | 0.80 | GPR119 (0.44) | MEN1ALDH1A1MAPTKMT2AGPR119 | |
| SCHEMBL2085186 | 0.80 | GPR119 (0.44) | MEN1ALDH1A1MAPTKMT2AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249145-B2 | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | MEN1 3611/4885ALDH1A1 3201/4885MAPT 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.